Artromac N.O.

At Artromac N.O. in Kosice, clinical research in immune system diseases focuses on conditions such as primary Sjögren’s disease, Sjögren’s syndrome, and systemic lupus erythematosus. These studies are designed to evaluate new treatment options and measure whether they can better control disease activity and improve patient outcomes.

• Studies in Sjögren’s disease and Sjögren’s syndrome are assessing whether new therapies can reduce symptoms and overall immune-related disease activity.
• Research in systemic lupus erythematosus is testing potential treatments aimed at improving responder rates and disease control.
• The site also contributes to work on broader autoimmune conditions where the goal is to strengthen symptom management and support better long-term care.

This area of research reflects a strong interest in therapies for chronic autoimmune disorders, with a focus on finding more effective and better-tolerated options for people living with these diseases.

The musculoskeletal diseases portfolio at this hospital/clinic includes rheumatoid arthritis and psoriatic arthritis, with studies aimed at easing inflammation, reducing joint symptoms, and improving daily function. These trials are evaluating new approaches to treatment effectiveness in common inflammatory joint diseases.

• Research in rheumatoid arthritis is exploring whether new therapies can better control moderate to severe disease activity.
• Trials in psoriatic arthritis are assessing symptom relief, reduced joint and skin involvement, and longer-term treatment benefit.
• The site is also involved in studies comparing newer biologic and immune-targeted treatments with placebo or standard care.

Overall, this therapeutic area centers on improving outcomes for people with persistent inflammatory arthritis through more precise and effective treatment strategies.

Research in skin and connective tissue diseases at Artromac N.O. includes subacute cutaneous lupus erythematosus and chronic cutaneous lupus erythematosus, along with related lupus conditions. The studies are focused on testing new therapies that may reduce skin disease activity and improve control of autoimmune symptoms.

• Trials in cutaneous lupus are examining whether investigational treatments can lower skin inflammation and disease severity.
• Studies also look at broader lupus manifestations to understand how treatment may help both skin and systemic involvement.
• The main goal is to improve disease management for patients whose symptoms remain difficult to control with existing options.

This research area highlights efforts to advance care for autoimmune skin conditions by identifying therapies that may offer stronger and more sustained benefit.

The site’s work in virus diseases includes studies in COVID-19 for nonhospitalized patients at high risk of developing severe illness. These trials are evaluating new antiviral treatment options intended to reduce the chance of worsening disease.

• Research in COVID-19 is focused on early treatment for people most likely to progress to serious illness.
• The purpose of these studies is to test whether new therapies can help limit complications and support recovery outside the hospital setting.
• This area adds an infectious disease dimension to the site’s broader portfolio of immune-mediated and inflammatory conditions.

Together, these trials show an emphasis on both chronic autoimmune disease and acute viral illness, with a common goal of improving treatment effectiveness and patient care.